15 results on '"Pfaender, Stephanie"'
Search Results
2. Frequent occurrence of nonprimate hepacivirus infections in Thoroughbred breeding horses – A cross-sectional study for the occurrence of infections and potential risk factors
- Author
-
Reichert, Claudia, Campe, Amely, Walter, Stephanie, Pfaender, Stephanie, Welsch, Kathrin, Ruddat, Inga, Sieme, Harald, Feige, Karsten, Steinmann, Eike, and Cavalleri, Jessika M.V.
- Published
- 2017
- Full Text
- View/download PDF
3. Frequent presence of hepaci and pegiviruses in commercial equine serum pools
- Author
-
Postel, Alexander, Cavalleri, Jessika-M. V., Pfaender, Stephanie, Walter, Stephanie, Steinmann, Eike, Fischer, Nicole, Feige, Karsten, Haas, Ludwig, and Becher, Paul
- Published
- 2016
- Full Text
- View/download PDF
4. Editorial overview: Coronaviruses 2024.
- Author
-
Pfaender, Stephanie and Steinmann, Eike
- Subjects
- *
CORONAVIRUSES - Published
- 2024
- Full Text
- View/download PDF
5. Inactivation of Zika virus in human breast milk by prolonged storage or pasteurization
- Author
-
Pfaender, Stephanie, Vielle, Nathalie J., Ebert, Nadine, Steinmann, Eike, Alves, Marco P., and Thiel, Volker
- Published
- 2017
- Full Text
- View/download PDF
6. Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2.
- Author
-
Kampf, G., Brüggemann, Y., Kaba, H.E.J., Steinmann, J., Pfaender, S., Scheithauer, S., Steinmann, E., Kampf, Günter, Brüggemann, Yannick, Kaba, Hani E J, Steinmann, Joerg, Pfaender, Stephanie, Scheithauer, Simone, and Steinmann, Eike
- Abstract
During the current SARS-CoV-2 pandemic new studies are emerging daily providing novel information about sources, transmission risks and possible prevention measures. In this review, we aimed to comprehensively summarize the current evidence on possible sources for SARS-CoV-2, including evaluation of transmission risks and effectiveness of applied prevention measures. Next to symptomatic patients, asymptomatic or pre-symptomatic carriers are a possible source with respiratory secretions as the most likely cause for viral transmission. Air and inanimate surfaces may be sources; however, viral RNA has been inconsistently detected. Similarly, even though SARS-CoV-2 RNA has been detected on or in personal protective equipment (PPE), blood, urine, eyes, the gastrointestinal tract and pets, these sources are currently thought to play a negligible role for transmission. Finally, various prevention measures such as handwashing, hand disinfection, face masks, gloves, surface disinfection or physical distancing for the healthcare setting and in public are analysed for their expected protective effect. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Temperature-dependent surface stability of SARS-CoV-2.
- Author
-
Kratzel, Annika, Steiner, Silvio, Todt, Daniel, V'kovski, Philip, Brueggemann, Yannick, Steinmann, Joerg, Steinmann, Eike, Thiel, Volker, and Pfaender, Stephanie
- Published
- 2020
- Full Text
- View/download PDF
8. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization.
- Author
-
Ebenig, Aileen, Muraleedharan, Samada, Kazmierski, Julia, Todt, Daniel, Auste, Arne, Anzaghe, Martina, Gömer, André, Postmus, Dylan, Gogesch, Patricia, Niles, Marc, Plesker, Roland, Miskey, Csaba, Gellhorn Serra, Michelle, Breithaupt, Angele, Hörner, Cindy, Kruip, Carina, Ehmann, Rosina, Ivics, Zoltan, Waibler, Zoe, and Pfaender, Stephanie
- Abstract
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads utilizing a severe hamster infection model: a T helper type 1 (T H 1)-biased measles vaccine-derived candidate and a T H 2-biased alum-adjuvanted, non-stabilized spike protein. The measles virus (MeV)-derived vaccine protects the animals, but the protein lead induces VAERD, which can be alleviated by dexamethasone treatment. Bulk transcriptomic analysis reveals that our protein vaccine prepares enhanced host gene dysregulation in the lung, exclusively up-regulating mRNAs encoding the eosinophil attractant CCL-11, T H 2-driving interleukin (IL)-19, or T H 2 cytokines IL-4, IL-5, and IL-13. Single-cell RNA sequencing (scRNA-seq) identifies lung macrophages or lymphoid cells as sources, respectively. Our findings imply that VAERD is caused by the concerted action of hyperstimulated macrophages and T H 2 cytokine-secreting lymphoid cells and potentially links VAERD to antibody-dependent enhancement (ADE). In summary, we identify the cytokine drivers and cellular contributors that mediate VAERD after T H 2-biased vaccination. [Display omitted] • T H 2-biased vaccines can prime immunopathogenesis in Syrian hamsters with COVID-19 • VAERD correlates with T H 2 cytokines and non-neutralizing antibodies • T cells, innate lymphoid cells, and lung macrophages are dysregulated in VAERD • VAERD can be treated with dexamethasone Ebenig et al. report vaccine-associated enhanced respiratory disease (VAERD) in SARS-CoV-2-infected Syrian hamsters previously immunized with a suboptimal vaccine consisting of misfolded SARS-CoV-2 spike protein and Alum adjuvants. VAERD is correlated with dysregulation of specific immune cell subsets in the lungs and could be alleviated by dexamethasone treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication.
- Author
-
von Hahn, Thomas, Schiene–Fischer, Cordelia, Van, Nguyen Dinh, Pfaender, Stephanie, Karavul, Behya, Steinmann, Eike, Potthoff, Andrej, Strassburg, Christian, Hamdi, Nabila, Abdelaziz, Ahmed I., Sarrazin, Christoph, Müller, Tobias, Berg, Thomas, Trépo, Eric, Wedemeyer, Heiner, Manns, Michael P., Pietschmann, Thomas, and Ciesek, Sandra
- Subjects
LIVER cells ,CYCLOPHILINS ,VIRAL replication ,HEPATITIS C virus ,MOLECULAR structure of RNA ,CELL culture ,SINGLE nucleotide polymorphisms ,GREEN fluorescent protein - Abstract
Background & Aims: Hepatitis C virus (HCV) uses several host factors to infect and replicate in human hepatocytes. Cyclophilin A (CypA) is required for viral replication, and CypA inhibitors are in development. We investigated the effects of nonsynonymous single nucleotide polymorphisms (SNPs) in the region of peptidyl-prolyl isomerase A (PPIA) that encodes CypA on HCV infection and replication of human hepatocytes. Methods: We used a combination of virologic, biochemical, and genetic approaches to investigate the effects of PPIA variants on HCV replication in cultured Huh-7.5 cells. We reduced levels of CypA in these cells using small hairpin RNAs (shRNAs). Results: Using shRNAs, we showed that CypA was required for replication of HCV in Huh-7.5 cells and identified 3 SNPs in PPIA that protected cells from HCV entry or replication. Levels of HCV RNA were reduced 3–4 log in cells homozygous for the variant alleles; release of new particles was also reduced, but viral entry was not affected. The effects of the variant alleles were recessive and stronger for preventing replication of full-length HCV genomes than subgenomes. CypA inhibitors prevented replication of residual HCV in hepatocytes. The variants appeared to destabilize the CypA protein; the single amino acid changes led to rapid degradation of the protein. Conclusions: We identified variants in PPIA that destabilize its product, CypA, and prevent HCV infection and replication. These findings indicate mechanisms by which some cells might be resistant to HCV infection and that CypA is a good therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Olfactory receptors impact pathophysiological processes of lung diseases in bronchial epithelial cells.
- Author
-
Weidinger, Daniel, Jacobsen, Julian, Alisch, Desiree, Uebner, Hendrik, Heinen, Natalie, Greune, Lea, Westhoven, Saskia, Jamal Jameel, Kaschin, Kronsbein, Juliane, Pfaender, Stephanie, Taube, Christian, Reuter, Sebastian, Peters, Marcus, Hatt, Hanns, and Knobloch, Jürgen
- Subjects
- *
WOUND healing , *BRONCHIAL diseases , *EPITHELIAL cells , *LUNG diseases , *OBSTRUCTIVE lung diseases , *VITALITY , *OLFACTORY receptors , *DRUG target - Abstract
Therapeutic options for steroid-resistant non-type 2 inflammation in obstructive lung diseases are limited. Bronchial epithelial cells are key in the pathogenesis by releasing the central proinflammatory cytokine interleukine-8 (IL-8). Olfactory receptors (ORs) are expressed in various cell types. This study examined the drug target potential of ORs by investigating their impact on associated pathophysiological processes in lung epithelial cells. Experiments were performed in the A549 cell line and in primary human bronchial epithelial cells. OR expression was investigated using RT-PCR, Western blot, and immunocytochemical staining. OR-mediated effects were analyzed by measuring 1) intracellular calcium concentration via calcium imaging, 2) cAMP concentration by luminescence-based assays, 3) wound healing by scratch assays, 4) proliferation by MTS-based assays, 5) cellular vitality by Annexin V/PI-based FACS staining, and 6) the secretion of IL-8 in culture supernatants by ELISA. By screening 100 potential OR agonists, we identified two, Brahmanol and Cinnamaldehyde, that increased intracellular calcium concentrations. The mRNA and proteins of the corresponding receptors OR2AT4 and OR2J3 were detected. Stimulation of OR2J3 with Cinnamaldehyde reduced 1) IL-8 in the absence and presence of bacterial and viral pathogen-associated molecular patterns (PAMPs), 2) proliferation, and 3) wound healing but increased cAMP. In contrast, stimulation of OR2AT4 by Brahmanol increased wound healing but did not affect cAMP and proliferation. Both ORs did not influence cell vitality. ORs might be promising drug target candidates for lung diseases with non-type 2 inflammation. Their stimulation might reduce inflammation or prevent tissue remodeling by promoting wound healing. • Lung epithelial cells are central in obstructive lung diseaes. • Extra nasal olfactory receptors (ORs) might impact molecular pathologies. • Drug target potential of ORs was investigated. • ORs differently impact cytokine secretion, cAMP signaling or cell growth. • OR2J3 has turned out as a promising drug target candidate. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Host determinants and responses underlying SARS-CoV-2 liver tropism.
- Author
-
Heinen, Natalie, Klöhn, Mara, Westhoven, Saskia, Brown, Richard JP, and Pfaender, Stephanie
- Subjects
- *
SARS-CoV-2 , *LIVER cells , *COVID-19 , *AUTOPSY - Abstract
Hepatic sequelae are frequently reported in coronavirus disease 2019 cases and are correlated with increased disease severity. Therefore, a detailed exploration of host factors contributing to hepatic impairment and ultimately infection outcomes in patients is essential for improved clinical management. The causes of hepatic injury are not limited to drug-mediated toxicity or aberrant host inflammatory responses. Indeed, multiple studies report the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in liver autopsies and the susceptibility of explanted human hepatocytes to infection. In this review, we confirm that hepatic cells express an extensive range of factors implicated in SARS-CoV-2 entry. We also provide an overview of studies reporting evidence for direct infection of liver cell types and the infection-induced cell-intrinsic processes that likely contribute to hepatic impairment. [Display omitted] • Hepatic manifestations in COVID-19 are driven by multifactorial mechanisms. • Hepatic cells express all reported SARS-CoV-2 entry factors. • SARS-CoV-2 can infect hepatocytes and is detected in liver specimens. • Infection of liver cells is proinflammatory and can cause direct hepatic injury. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
- Author
-
Behrendt, Patrick, Perin, Paula, Menzel, Nicolas, Banda, Dominic, Pfaender, Stephanie, Alves, Marco P., Thiel, Volker, Meuleman, Philip, Colpitts, Che C., Schang, Luis M., Vondran, Florian W.R., Anggakusuma, null, Manns, Michael P., Steinmann, Eike, and Pietschmann, Thomas
- Subjects
- *
PENTAGALLOYLGLUCOSE , *POLYPHENOLS , *HEPATITIS C virus , *ANTIVIRAL agents , *LIVER transplantation - Abstract
Approximately 142 million people worldwide are infected with hepatitis C virus (HCV). Although potent direct acting antivirals are available, high costs limit access to treatment. Chronic hepatitis C virus infection remains a major cause of orthotopic liver transplantation. Moreover, re-infection of the graft occurs regularly. Antivirals derived from natural sources might be an alternative and cost-effective option to complement therapy regimens for global control of hepatitis C virus infection. We tested the antiviral properties of a mixture of different Chinese herbs/roots named Zhi Bai Di Huang Wan (ZBDHW) and its individual components on HCV. One of the ZBDHW components, Penta-O-Galloyl-Glucose (PGG), was further analyzed for its mode of action in vitro , its antiviral activity in primary human hepatocytes as well as for its bioavailability and hepatotoxicity in mice. ZBDHW, its component Cortex Moutan and the compound PGG efficiently block entry of HCV of all major genotypes and also of the related flavivirus Zika virus. PGG does not disrupt HCV virion integrity and acts primarily during virus attachment. PGG shows an additive effect when combined with the well characterized HCV inhibitor Daclatasvir. Analysis of bioavailability in mice revealed plasma levels above tissue culture IC 50 after a single intraperitoneal injection. In conclusion, PGG is a pangenotypic HCV entry inhibitor with high bioavailability. The low cost and wide availability of this compound make it a promising candidate for HCV combination therapies, and also emerging human pathogenic flaviviruses like ZIKV. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial.
- Author
-
Meister, Toni Luise, Gottsauner, Josef-Maximilian, Schmidt, Barbara, Heinen, Natalie, Todt, Daniel, Audebert, Franz, Buder, Felix, Lang, Henriette, Gessner, André, Steinmann, Eike, Vielsmeier, Veronika, Pfaender, Stephanie, and Cieplik, Fabian
- Subjects
- *
AIRBORNE infection , *ANTIVIRAL agents , *SARS-CoV-2 , *CLINICAL trials , *VIRAL envelopes - Abstract
• BAC and other antiseptics showed high antiviral efficacy in vitro. • BAC and other antiseptics disrupt the viral envelope. • Mouthrinses with a single antiseptic compound appear to reduce viral transmission rates to a minor extent. The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upon the use of antiseptic mouthrinses as a way to possibly reduce infectious viral titers. However, clinical evaluations are still sparse. Thus, we evaluated a wide variety of antiseptic agents that can be used as mouthrinses for their antiviral effects in vitro and their respective mode of action. One of the most promising antiseptic agents (benzalkoniumchloride, BAC) was used in a randomized placebo-controlled clinical trial with subsequent analysis of viral loads by RT-qPCR and virus rescue in cell culture. Mechanistic analysis revealed that treatment with BAC and other antiseptic agents efficiently inactivated SARS-CoV-2 in vitro by primarily disrupting the viral envelope, without affecting viral RNA integrity. However, the clinical application only resulted in a mild reduction of viral loads in the oral cavity. These results indicate that gargling with mouthrinses comprising single antiseptic agents may play a minor role towards a potential reduction of transmission rates and thus, these findings are of utmost importance when considering alternative COVID-19 prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
- Author
-
Stegmann, Kim M., Dickmanns, Antje, Gerber, Sabrina, Nikolova, Vella, Klemke, Luisa, Manzini, Valentina, Schlösser, Denise, Bierwirth, Cathrin, Freund, Julia, Sitte, Maren, Lugert, Raimond, Salinas, Gabriela, Meister, Toni Luise, Pfaender, Stephanie, Görlich, Dirk, Wollnik, Bernd, Groß, Uwe, and Dobbelstein, Matthias
- Subjects
- *
INOSINE , *ANTIVIRAL agents , *SARS-CoV-2 , *FOLIC acid antagonists , *REMDESIVIR , *COVID-19 , *METHOTREXATE - Abstract
• MTX is one of the earliest cancer drugs to be developed, giving rise to seven decades of clinical experience. It is on the World Health Organization's List of Essential Medicines, can be administered orally or parenterally, and its costs are at single digit € or $ amounts/day for standard treatment. In case of its successful further preclinical evaluation for treating SARS-CoV-2 infections, its repurposing to treat COVID-19 would thus be feasible, especially under low-resource conditions. • Additional drugs exist to interfere with the synthesis of nucleotides, e.g. additional folate antagonists, inhibitors of GMP synthetase, or inhibitors of dihydroorotate dehydrogenase (DHODH). Such inhibitors have been approved as drugs for different purposes and might represent further therapeutic options against infections with SARS-CoV-2. • Remdesivir is in clinical trials for treating COVID-19. Our results argue that MTX and remdesivir, even at moderate concentrations, can act in a synergistic fashion to repress virus replication to a considerably greater extent than either drug alone. • COVID-19, in its severe forms, is characterized by pneumonia and acute respiratory distress syndrome, and additional organ involvements. These manifestations are not necessarily a direct consequence of virus replication and cytopathic effects, but rather a result of an uncontrolled inflammatory and immune response. Anti-inflammatory drugs such as glucocorticoids are thus being evaluated for treating COVID-19. However, this bears the risk of re-activating virus spread by suppressing a sufficient and specific immune response. In this situation, it is tempting to speculate that MTX might suppress both excessive inflammation as well as virus replication at the same time, thus limiting both the pathogenesis of pneumonia and also the spread of virus within a patient. The search for successful therapies of infections with the coronavirus SARS-CoV-2 is ongoing. We tested inhibition of host cell nucleotide synthesis as a promising strategy to decrease the replication of SARS-CoV-2-RNA, thus diminishing the formation of virus progeny. Methotrexate (MTX) is an established drug for cancer therapy and to induce immunosuppression. The drug inhibits dihydrofolate reductase and other enzymes required for the synthesis of nucleotides. Strikingly, the replication of SARS-CoV-2 was inhibited by MTX in therapeutic concentrations around 1 µM, leading to more than 1000-fold reductions in virus progeny in Vero C1008 (Vero E6) and ~100-fold reductions in Calu-3 cells. Virus replication was more sensitive to equivalent concentrations of MTX than of the established antiviral agent remdesivir. MTX strongly diminished the synthesis of viral structural proteins and the amount of released virus RNA. Virus replication and protein synthesis were rescued by folinic acid (leucovorin) and also by inosine, indicating that purine depletion is the principal mechanism that allows MTX to reduce virus RNA synthesis. The combination of MTX with remdesivir led to synergistic impairment of virus replication, even at 100 nM MTX. The use of MTX in treating SARS-CoV-2 infections still awaits further evaluation regarding toxicity and efficacy in infected organisms, rather than cultured cells. Within the frame of these caveats, however, our results raise the perspective of a two-fold benefit from repurposing MTX for treating COVID-19. Firstly, its previously known ability to reduce aberrant inflammatory responses might dampen respiratory distress. In addition, its direct antiviral activity described here would limit the dissemination of the virus. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay.
- Author
-
Wollschläger, Paul, Todt, Daniel, Gerlitz, Nadja, Pfaender, Stephanie, Bollinger, Thomas, Sing, Andreas, Dangel, Alexandra, Ackermann, Nickolaus, Korn, Klaus, Ensser, Armin, Steinmann, Eike, Buhl, Michael, and Steinmann, Joerg
- Subjects
- *
SARS-CoV-2 , *EXOMES , *RECEIVER operating characteristic curves , *GENETIC vectors , *NUCLEOTIDE sequencing - Abstract
Detection and surveillance of SARS-CoV-2 is of eminent importance, particularly due to the rapid emergence of variants of concern (VOCs). In this study we evaluated if a commercially available quantitative real-time PCR (qRT-PCR) assay can identify SARS-CoV-2 B.1.1.7 lineage samples by a specific N gene dropout or Ct value shift compared with the S or RdRp gene. VOC B.1.1.7 and non-B.1.1.7 SARS-CoV-2-positive patient samples were identified via whole-genome sequencing and variant-specific PCR. Confirmed B.1.1.7 (n = 48) and non-B.1.1.7 samples (n = 58) were analysed using the Allplex™ SARS-CoV-2/FluA/FluB/RSV™ PCR assay for presence of SARS-CoV-2 S , RdRp and N genes. The N gene coding sequence of SARS-CoV-2 with and without the D3L mutation (specific for B.1.1.7) was cloned into pCR™II-TOPO™ vectors to validate polymorphism-dependent N gene dropout with the Allplex™ SARS-CoV-2/FluA/FluB/RSV™ PCR assay. All studied B.1.1.7-positive patient samples showed significantly higher Ct values in qRT-PCR (Δ6–10, N gene dropout on Ct values > 29) of N gene than the corresponding values of S (p ≤ 0.0001) and RdRp (p ≤ 0.0001) genes. The assay reliably discriminated B.1.1.7 and non-B.1.1.7 positive samples (area under the curve = 1) in a receiver operating characteristic curve analysis. Identical Ct value shifts (Δ7–10) were detected in reverse genetic experiments, using isolated plasmids containing N gene coding sequences corresponding to D3 or 3L variants. An N gene dropout or Ct value shift is shown for B.1.1.7-positive samples in the Allplex™ SARS-CoV-2/FluA/FluB/RSV™ PCR assay. This approach can be used as a rapid tool for B.1.1.7 detection in single assay high throughput diagnostics. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.